Southern Research Received $8 Million for Biomedical Hub
The Birmingham-based facility aims to reduce animal testing by developing human-relevant research models.
Updated on Oct. 13, 2026 in Life Sciences
Live Poll
Do you believe replacing animal testing with human-relevant models improves the drug development process?
Southern Research secured an $8 million grant from the National Institutes of Health to establish a shared-use facility in Birmingham. The project will focus on creating new approach methodologies to support drug discovery and development.
Why it matters
The center aims to decrease reliance on animal models in pharmaceutical research by integrating advanced analytics and human-relevant data. This initiative provides a centralized environment for government, industry, and academic researchers to validate these new testing methods.
The grant funds an $8 million investment to build the Translational Hub for Research, Innovation, Validation, and Excellence. This facility will integrate laboratory and computational tools to benchmark the performance of new approach methodologies that mimic human biological responses.
The players
Southern Research
A nonprofit research organization focused on drug discovery, development, and clinical trial support.
National Institutes of Health
The primary federal agency responsible for biomedical and public health research.
The details
The facility will employ new approach methodologies—scientific techniques that use human-relevant models and advanced data to replace or reduce animal testing. By consolidating laboratory, computational, and data-oriented workflows, the center aims to create a cohesive environment for researchers to validate predictive models. Investigators from the National Institutes of Health, the federal government, and the pharmaceutical industry will access these resources to refine their drug development pipelines.
Timeline
October 13, 2026: The project was announced.
The Tech Race
This project aligns with the broader federal effort to shift pharmaceutical validation away from legacy animal-based models. It positions the new Birmingham facility as a central hub for benchmarking the performance of emerging human-relevant methodologies against established industry standards.
The hub will initially provide researchers from pharmaceutical firms and government institutions with standardized access to validation data. Over time, these methods aim to improve the accuracy of human clinical trials by filtering out ineffective drug candidates earlier in the development lifecycle.
The takeaway
The creation of this hub signals an industry-wide transition toward validated, non-animal modeling for drug development. Stakeholders should track the center's future performance benchmarks as they look to replace conventional preclinical trials with these new approach methodologies.
Further reading
Explore more developments in Life Sciences to see how new research methods are impacting drug discovery timelines.
Source note: This article includes information reported by Pharmaceutical Technology.
Live Poll
Do you believe replacing animal testing with human-relevant models improves the drug development process?
